CHU Gabriel-Montpied

At CHU Gabriel-Montpied the nephrology unit focuses on advancing treatments for chronic kidney conditions, transplant outcomes, and immune‑mediated renal diseases.

• Chronic Kidney Disease
• IgA nephropathy
• Lupus Nephritis
• Kidney Transplantation
• BKV infection
• Glycogen storage disease type II

With 62 active trials and a team of 65 investigators, the department evaluates novel therapies, preventive strategies, and diagnostic tools to preserve renal function.

The site conducts studies targeting a range of solid tumours, aiming to improve survival and reduce recurrence through innovative drug combinations and immunotherapies.

• Non‑small cell lung cancer
• Gastric and gastro‑esophageal junction cancer with FGFR2b overexpression
• Bladder carcinoma in situ (BCG‑unresponsive)
• Head and neck cancer
• Penile carcinoma
• Pleural mesothelioma

These 62 trials include investigations of targeted agents, checkpoint inhibitors, and antibody‑drug conjugates, reflecting a strong commitment to personalized oncology.

Research in the neurological field explores disease‑modifying approaches for multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis, seeking to slow progression and improve quality of life.

• Relapsing multiple sclerosis
• Primary progressive multiple sclerosis
• Early Parkinson’s disease
• Amyotrophic Lateral Sclerosis
• Diffuse intrinsic pontine glioma
• Chronic inflammatory demyelinating polyneuropathy

The collaborative effort leverages advanced imaging and biomarkers to assess therapeutic impact across 62 trials.

Investigations address atherosclerotic disease, heart failure, and obesity‑related cardiovascular risk, testing novel lipid‑lowering agents and heart‑failure management strategies.

• Atherosclerotic cardiovascular disease
• Heart failure with recovered ejection fraction
• Inclisiran for cardiovascular events
• Obesity and weight management
• Venous thromboembolism
• Pulmonary arterial hypertension

The department’s trials aim to reduce major adverse cardiac events and improve long‑term vascular health.

Clinical work in the respiratory area evaluates treatments for lung cancer, pulmonary hypertension, and severe pneumonia, focusing on survival and functional outcomes.

• Stage III unresectable NSCLC
• Inoperable chronic thromboembolic pulmonary hypertension
• Hospital‑acquired pneumonia
• Acute respiratory failure in immunocompromised patients
• Pulmonary arterial hypertension
• NSCLC with KRAS G12C mutation

Trials incorporate immunotherapy, targeted therapy, and novel anticoagulation regimens to address unmet needs.

The centre evaluates biologic agents for immune‑mediated diseases such as lupus, IgA nephropathy, and myasthenia gravis, aiming to modulate pathogenic pathways.

• Systemic lupus erythematosus
• Lupus nephritis
• IgA nephropathy
• Generalized myasthenia gravis
• VEXAS syndrome
• Bacterial vaginosis

These studies test complement inhibitors, BTK inhibitors, and immunoglobulin therapies to achieve disease control.

Focused on preventing viral reactivation and bacterial complications, the site’s trials assess prophylactic immunoglobulins and antiviral strategies in transplant recipients.

• BKV infection in kidney transplant
• EBV primary infection prevention
• Hospital‑acquired pneumonia
• Bacterial vaginosis
• Virus diseases
• Bacterial infections and mycoses

By integrating virology and immunology, the program supports safer transplantation and reduced infection‑related morbidity.